Enzalutamide (XTANDI) is a prescription medicine used to treat men with prostate cancer that no longer responds to a medical or surgical treatment that lowers testosterone. XTANDI is now approved to treat men with prostate cancer that no longer responds to treatment that lowers testosterone and has not spread to other parts of the body. This is also known as non-metastatic castration-resistant prostate cancer (CRPC).
This web page, published by the National Cancer Institute, lists the clinical trials using Enzalutamide. Click here to view the article.
The 2018 Genitourinary Cancers Symposium event featured groundbreaking research among members of the cancer care and research community who diagnose, treat, and study genitourinary malignancies.
Click on the below links to view conference proceedings on
The approved treatments for prostate cancer available today were made possible because patients participated in clinical trials. Through clinical trials, doctors find new and better ways to prevent, detect, diagnose, control, and treat illnesses.
However, finding an appropriate clinical trial can be challenging. We encourage you to simplify the process with The Us TOO Prostate Cancer Clinical Trial Finder, a free and confidential service that provides an efficient, user-friendly, customized approach to identify clinical trials relevant for each individual prostate cancer patient.
Read more and access the Us TOO Prostate Cancer Clinical Trial Finder
The minimally invasive treatment uses steam to kill cells and shrink the prostate and can be used on a wider range of anatomies.
Early results in clinical practice on large prostates appear “promising” and a study on prostates up to 150 grams is expected to begin later this year.
Read more on Wall Street Journal